Journals / Turkish Journal of Urology / 2021 / Cilt: 47 - Sayı: 1

The role of surgery in high risk and advanced prostate cancer: A narrative review

Pages
S56–S64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Emerging imaging modalities enabling more accurate staging and longer follow-up of clinical trials for prognostic endpoints are anticipated to help identify patient cohorts and treatment strategies, where the use of surgical treatments is likely to provide oncological benefits and acceptable toxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Patients with high-risk and advanced prostate cancer require safe and efficacious therapies likely to offer a survival advantage while minimizing the treatment-related toxicities.
📊
Key Findings & Data:Improvements in the surgical technology, diagnostic modalities, radiological staging, and risk stratification have made surgery for high-risk and advanced prostate cancer a safe and feasible option.
💡
Conclusion & Impact:Emerging imaging modalities enabling more accurate staging and longer follow-up of clinical trials for prognostic endpoints are anticipated to help identify patient cohorts and treatment strategies, where the use of surgical treatments is likely to provide oncological benefits and acceptable toxicity.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Patients with high-risk and advanced prostate cancer require safe and efficacious therapies likely to offer a survival advantage while minimizing the treatment-related toxicities. Improvements in the surgical technology, diagnostic modalities, radiological staging, and risk stratification have made surgery for high-risk and advanced prostate cancer a safe and feasible option. In this review, we outline the role of radical prostatectomy in high-risk localized, locally advanced, and metastatic prostate cancer. We overview available data evaluating the use of surgery in the context of a multi-modal approach and highlight ongoing trials in this area. Furthermore, the role of surgery as a non-systemic modality for metastasis-directed therapy (MDT) is also described. Emerging imaging modalities enabling more accurate staging and longer follow-up of clinical trials for prognostic endpoints are anticipated to help identify patient cohorts and treatment strategies, where the use of surgical treatments is likely to provide oncological benefits and acceptable toxicity.

🔖

Cite This Article

ROY, C. S. D., SACHDEVA, A., KANDASWAMY, G., RAİ, B. (2021). The role of surgery in high risk and advanced prostate cancer: A narrative review. Turkish Journal of Urology, Cilt: 47 - Sayı: 1, S56–S64. https://ajindex.com/articles/413260

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028-38. [Crossref] 2. James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol 2016;2:348-57. [Crossref] 3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969- 74. [Crossref] 4. Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020. European Association of Urology Guidelines 2020 Edition. presented at the EAU Annual Congress Amsterdam 2020.
  2. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020. 5. National Comprehensive Cancer Network (NCCN). Prostate Cancer (Version 2.2020) [Guidelines]. 2020 [updated 21 May 2020; cited 2020 16 August]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. 6. National Institute for Health and Care Excellence. NICE guideline [NG131]: Prostate cancer: diagnosis and management. 2019 May. Report No. 7. Sanda M, Chen R, Crispino T, Freedland S, Greene K, Klotz L, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. American Urological Association. 2017 April. 8. Mossanen M, Nepple KG, Grubb RL, 3rd, Androile GL, Kallogjeri D, Klein EA, et al. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol 2018;1:143-8. [Crossref] 9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37. [Crossref] 10. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71:618-29. [Crossref] 11. Stranne J, Brasso K, Brennhovd B, Johansson E,